{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:19:14Z","timestamp":1791227954115,"version":"4.1.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Spironolactone, an aldosterone antagonist, has been demonstrated to decrease mortality in human patients when added to other cardiac therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Hypothesis<\/jats:title>\n                    <jats:p>Spironolactone in addition to conventional therapy increases survival compared with conventional therapy in dogs with naturally occurring myxomatous mitral valve disease (MMVD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Between February 2003 and March 2005, 221 dogs were recruited in Europe. Nine dogs were excluded from analysis, leaving 212 dogs with moderate to severe mitral regurgitation (MR) caused by MMVD (International Small Animal Cardiac Health Council classification classes II [n = 190] and III [n = 21]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Double-blinded, field study conducted with dogs randomized to receive either spironolactone (2\u2003mg\/kg once a day) or placebo in addition to conventional therapy (angiotensin converting enzyme inhibitor, plus furosemide and digoxin if needed). Primary endpoint was a composite of cardiac-related death, euthanasia, or severe worsening of MR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Primary endpoint reached by 11\/102 dogs (10.8%) in the spironolactone group (6 deaths, 5 worsening) versus 28\/110 (25.5%) in control group (14 deaths, 8 euthanasia, 6 worsening). Risk of reaching the composite endpoint significantly decreased by 55% (hazard ratio [HR] = 0.45; 95% confidence limits [CL], 0.22\u20130.90; log rank test, P= .017). Risk of cardiac- related death or euthanasia significantly reduced by 69% (HR = 0.31; 95% CL, 0.13\u20130.76; P= .0071). Number of dogs not completing the study for cardiac and other miscellaneous reasons similar in spironolactone (67\/102) and control groups (66\/110).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion and Clinical Importance<\/jats:title>\n                    <jats:p>Spironolactone added to conventional cardiac therapy decreases the risk of reaching the primary endpoint (ie, cardiac-related death, euthanasia, or severe worsening) in dogs with moderate to severe MR caused by MMVD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1939-1676.2009.0467.x","type":"journal-article","created":{"date-parts":[[2010,1,25]],"date-time":"2010-01-25T15:00:49Z","timestamp":1264431649000},"page":"331-341","source":"Crossref","is-referenced-by-count":87,"title":["Efficacy of Spironolactone on Survival in Dogs with Naturally Occurring Mitral Regurgitation Caused by Myxomatous Mitral Valve Disease"],"prefix":"10.1093","volume":"24","author":[{"given":"F.","family":"Bernay","sequence":"first","affiliation":[{"name":"Ceva Sant\u00e9 Animale R&D Department, , Libourne,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Bland","sequence":"additional","affiliation":[{"name":"University of York Department of Health Sciences, , Heslington,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"H\u00e4ggstr\u00f6m","sequence":"additional","affiliation":[{"name":"Faculty of Veterinary Medicine and Animal Science, Swedish University of Agricultural Sciences Department of Clinical Sciences, , Uppsala,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Baduel","sequence":"additional","affiliation":[{"name":"Ceva Sant\u00e9 Animale R&D Department, , Libourne,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Combes","sequence":"additional","affiliation":[{"name":"Stalphamis, Lalande de Pomerol ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lopez","sequence":"additional","affiliation":[{"name":"Ceva Sant\u00e9 Animale R&D Department, , Libourne,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Kaltsatos","sequence":"additional","affiliation":[{"name":"Ceva Sant\u00e9 Animale R&D Department, , Libourne,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2010,3,1]]},"reference":[{"key":"2026020303143331400_b1","first-page":"321","article-title":"Fiftieth anniversary of aldosterone","volume":"96","author":"Tan","year":"2004","journal-title":"From discovery to cardiovascular therapy"},{"key":"2026020303143331400_b2","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1161\/01.CIR.83.6.1849","article-title":"Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system","volume":"83","author":"Weber","year":"1991","journal-title":"Circulation"},{"key":"2026020303143331400_b3","first-page":"425","article-title":"Aldosterone induces acute endothelial dysfunction in vivo in humans","volume":"103","author":"Farquharson","year":"2002","journal-title":"Evidence for an aldosterone-induced vasculopathy"},{"key":"2026020303143331400_b4","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1161\/01.HYP.0000078357.92682.EC","article-title":"Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling","volume":"42","author":"Pu","year":"2003","journal-title":"Hypertension"},{"key":"2026020303143331400_b5","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/cvr\/26.7.671","article-title":"Reactive and reparative myocardial fibrosis in arterial hypertension in the rat","volume":"26","author":"Brilla","year":"1992","journal-title":"Cardiovasc Res"},{"key":"2026020303143331400_b6","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1006\/jmcc.1993.1066","article-title":"Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism","volume":"25","author":"Brilla","year":"1993","journal-title":"J Mol Cell Cardiol"},{"key":"2026020303143331400_b7","first-page":"145","article-title":"\u2018Escape\u2019 of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor","volume":"9","author":"Pitt","year":"1995","journal-title":"Implications for therapy"},{"key":"2026020303143331400_b8","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.2460\/ajvr.1996.57.11.1645","article-title":"Effects of long-term treatment with enalapril or hydralazine on the renin-angiotensin-aldosterone system and fluid balance in dogs with naturally acquired mitral valve regurgitation","volume":"57","author":"H\u00e4ggstr\u00f6m","year":"1996","journal-title":"Am J Vet Res"},{"key":"2026020303143331400_b9","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1939-1676.2002.tb01610.x","article-title":"Efficacy of enalapril for prevention of congestive heart failure in dogs with myxomatous valve disease and asymptomatic mitral regurgitation","volume":"16","author":"Kvart","year":"2002","journal-title":"J Vet Intern Med"},{"key":"2026020303143331400_b10","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2460\/javma.231.7.1061","article-title":"Results of the veterinary enalapril trial to prove reduction in onset of heart failure in dogs chronically treated with enalapril alone for compensated, naturally occurring mitral valve insufficiency","volume":"231","author":"Atkins","year":"2007","journal-title":"J Am Vet Med Assoc"},{"key":"2026020303143331400_b11","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.2460\/ajvr.69.12.1664","article-title":"Assessment of diuretic effects and changes in plasma aldosterone concentration following oral administration of a single dose of furosemide or azosemide in healthy dogs","volume":"69","author":"Hori","year":"2008","journal-title":"Am J Vet Res"},{"key":"2026020303143331400_b12","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2165\/00003495-200262050-00001","article-title":"Rationale for the use of aldosterone antagonists in congestive heart failure","volume":"62","author":"Rocha","year":"2002","journal-title":"Drugs"},{"key":"2026020303143331400_b13","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Eng J Med"},{"key":"2026020303143331400_b14","author":"US Department of Health and Human Services, Food and Drug Administration, Center for Veterinary Medicine."},{"key":"2026020303143331400_b15","first-page":"100","article-title":"Echocardiographie et echo-doppler du chien et du chat, Chapter 3","author":"Chetboul","year":"1999","edition":"1st ed"},{"key":"2026020303143331400_b16","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2460\/javma.1995.206.02.194","article-title":"Vertebral scale system to measure canine heart size in radiographs","volume":"206","author":"Buchanan","year":"1995","journal-title":"J Am Vet Med Assoc"},{"key":"2026020303143331400_b17","author":"Elliot"},{"key":"2026020303143331400_b18","first-page":"883","article-title":"Textbook of Canine and Feline Cardiology: Principles and Clinical Practice","author":"Fox","year":"1999","edition":"2nd ed"},{"key":"2026020303143331400_b19","first-page":"1339","article-title":"Intention-to-treat principle","volume":"165","author":"Montori","year":"2001","journal-title":"Can Med Assoc J"},{"key":"2026020303143331400_b20","first-page":"1","article-title":"Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease","author":"H\u00e4ggstr\u00f6m","year":"2008","journal-title":"The Quest study"},{"key":"2026020303143331400_b21","first-page":"7","article-title":"The effect of benazepril on survival times and clinical signs of dogs with congestive heart failure","volume":"1","author":"The BENCH Study Group.","year":"1999","journal-title":"Results of a multicenter, prospective, randomized, double-blinded, placebo-controlled, long-term clinical trial"},{"key":"2026020303143331400_b22","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.2460\/javma.1998.213.11.1573","article-title":"Effects of enalapril maleate on survival of dogs with naturally acquired heart failure","volume":"213","author":"Ettinger","year":"1998","journal-title":"J Am Vet Med Assoc"},{"key":"2026020303143331400_b23","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1161\/01.HYP.0000034738.79310.06","article-title":"Spironolactone improves angiotensin-induced vascular changes and oxidative stress","volume":"40","author":"Virdis","year":"2002","journal-title":"Hypertension"},{"key":"2026020303143331400_b24","first-page":"1773","article-title":"Aldosterone-induced inflammation in the rat heart","volume":"161","author":"Sun","year":"2002","journal-title":"Role of oxidative stress"},{"key":"2026020303143331400_b25","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1046\/j.1523-1755.2003.00929.x","article-title":"Aldosterone\/salt induces renal inflammation and fibrosis in hypertensive rats","volume":"63","author":"Blasi","year":"2003","journal-title":"Kidney Int"},{"key":"2026020303143331400_b26","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1053\/euhj.1998.1099","article-title":"Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients","volume":"19","author":"Duprez","year":"1998","journal-title":"Eur Heart J"},{"key":"2026020303143331400_b27","first-page":"3","article-title":"Aldosterone and cardiovascular remodelling","volume":"5","author":"Shieh","year":"2004","journal-title":"Focus on myocardial failure"},{"key":"2026020303143331400_b28","first-page":"2700","article-title":"Limitation of excessive extra-cellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure","volume":"102","author":"Zannad","year":"2000","journal-title":"Insights from the randomized aldactone evaluation study (RALES). Rales investigators"},{"key":"2026020303143331400_b29","first-page":"H961","article-title":"Volume-overload cardiac hyperthrophy is unaffected by ACE inhibitor treatment in dogs","volume":"273","author":"Dell Italia","year":"1997","journal-title":"Am J Physiol"},{"key":"2026020303143331400_b30","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.carpath.2006.04.003","article-title":"Arteriosclerotic changes in the myocardium, lung, and kidney in dogs with chronic congestive heart failure and myxomatous mitral valve disease","volume":"15","author":"Falk","year":"2006","journal-title":"Cardiovasc Pathol"},{"key":"2026020303143331400_b31","author":"Falk"},{"key":"2026020303143331400_b32","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00029330-200801010-00008","article-title":"Effects of spironolactone on electrical and structural remodeling of atrium in congestive heart failure dogs","volume":"121","author":"Yang","year":"2008","journal-title":"Chin Med J"},{"key":"2026020303143331400_b33","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1161\/01.CIR.0000039104.56479.42","article-title":"Effects of a long-term monotherapy with Eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodelling in dogs with heart failure","volume":"106","author":"Suzuki","year":"2002","journal-title":"Circulation"},{"key":"2026020303143331400_b34","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.cvsm.2004.05.018","article-title":"Use of pimobendan in the management of heart failure","volume":"34","author":"Fuentes","year":"2004","journal-title":"Vet Clin North Am Small Anim Pract"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1939-1676.2009.0467.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/24\/2\/331\/66654469\/j.1939-1676.2009.0467.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/24\/2\/331\/66654469\/j.1939-1676.2009.0467.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T08:14:42Z","timestamp":1770106482000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/24\/2\/331\/8447303"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,1]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,3,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1939-1676.2009.0467.x","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2010,3]]},"published":{"date-parts":[[2010,3,1]]}}}